Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients
NCT ID: NCT00973466
Last Updated: 2011-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2009-05-31
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study hypothesis: STI prevalence is high in certain risk-groups to justify screening in regular intervals.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterization of Acute and Recent HIV-1 Infections in Zurich.
NCT00537966
Analysis of HIV-1 Replication During Antiretroviral Therapy
NCT00767312
Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other Infections
NCT00000858
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
NCT00857350
A Study of the Long-Term Outcomes of HIV-Positive Patients
NCT00000932
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HIV-infection
All HIV-infected patients attending the Clinic for Infectious Diseases at Berne university hospital, having been sexually active during the past 12 months and having given written informed consent
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Attending the Clinic for Infectious Diseases from May 09 to November 09
* Sexually active during the last 12 months
* Written informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital Inselspital, Berne
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hansjakob Furrer, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Berne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinic for Infectious Diseases, Berne University Hospital
Bern, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KEK26/09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.